Is GMAB or GRCE more undervalued in 2026?

CirclFi compares Genmab A/S (GMAB) and Grace Therapeutics, Inc. (GRCE) using 13 institutional-grade valuation models. GMAB has a Quality of Company score of 6.7/10 while GRCE scores 4.6/10.

Which is a better buy — GMAB or GRCE?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do GMAB and GRCE valuations compare?

GMAB at $27.04 and GRCE at $2.43 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

GMAB vs GRCE Valuation Comparison 2026 — Intrinsic Value Analysis

GMAB

Biotechnology

Genmab A/S

Quality

6.7

out of 10

Value Trap

—

Price

$27.04

Last close

Models

13/13

Active

GRCE

Biotechnology

Grace Therapeutics, Inc.

Quality

4.6

out of 10

Value Trap

WARN

Price

$2.43

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	GMAB Fair Value	GMAB Upside	GRCE Fair Value	GRCE Upside
Bayesian DCF	Intrinsic	$29.51	+9.1%	$1.31	-46.0%
Earnings Power Value	Intrinsic	$22.31	-17.5%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$59.18	+118.9%	$4.05	+66.7%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for GMAB vs GRCE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GMAB vs GRCE — Which Stock Is More Undervalued?

GMAB scores higher with a 6.7/10 quality rating vs GRCE's 4.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Genmab A/S (GMAB) and Grace Therapeutics, Inc. (GRCE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GMAB currently trades at $27.04 with a QOC of 6.7/10, while GRCE trades at $2.43 with a QOC of 4.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).